NCT07285096招募中不适用
Efficacy and Safety of P-CABs-Based Bismuth Quadruple Therapy for First-line Helicobacter Pylori Eradication: A Multicenter Cohort Study
Yueyue Li1 个研究点 分布在 1 个国家目标入组 1,730 人开始时间: 2025年12月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,730
- 试验地点
- 1
- 主要终点
- Eradication rate
研究概览
简要总结
Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various potassium-competitive acid blockers (P-CABs) -based bismuth quadruple regimens and identify factors influencing treatment failure. A multicenter cohort study was conducted and study outcomes included eradication rates and incidence of adverse events.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients aged 18-70 years, regardless of gender;
- •willing to receive H. pylori eradication therapy;
- •diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.
排除标准
- •patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;
- •patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.
结局指标
主要结局
Eradication rate
时间窗: 6-8 weeks after treatment completion
Comparison of eradication rates among quadruple therapies for Helicobacter pylori
次要结局
- Adverse events(lmmediately after treatment completion)
研究者
Yueyue Li
Associate Professor
Qilu Hospital of Shandong University
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer DiseaseHelicobacter Pylori InfectionPeptic UlcerNCT07260006Can Tho University of Medicine and Pharmacy80
进行中(未招募)
不适用
匹维溴铵片在中国健康受试者中的生物等效性试验CTR2024423356
进行中(未招募)
不适用
匹维溴铵片在中国健康受试者中的生物等效性试验CTR2024423248
已完成
不适用
布瑞哌唑片在健康人体内的生物等效性试验CTR2024009972
进行中(未招募)
2 期
巴布奇搽剂治疗白癜风(稳定期)临床试验CTR20182023240
